148 related articles for article (PubMed ID: 35409084)
21. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
22. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.
Liu G; Shuman MA; Cohen RL
Int J Cancer; 1995 Feb; 60(4):501-6. PubMed ID: 7829264
[TBL] [Abstract][Full Text] [Related]
23. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
24. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
25. (-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
Shin S; Kim MK; Jung W; Chong Y
Phytother Res; 2018 Oct; 32(10):2086-2096. PubMed ID: 30009577
[TBL] [Abstract][Full Text] [Related]
26. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Zhou L; Hayashi Y; Itoh T; Wang W; Rui J; Itoh H
Pathol Int; 2000 May; 50(5):392-7. PubMed ID: 10849328
[TBL] [Abstract][Full Text] [Related]
27. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract][Full Text] [Related]
28. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
29. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
30. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Setyono-Han B; Stürzebecher J; Schmalix WA; Muehlenweg B; Sieuwerts AM; Timmermans M; Magdolen V; Schmitt M; Klijn JG; Foekens JA
Thromb Haemost; 2005 Apr; 93(4):779-86. PubMed ID: 15841327
[TBL] [Abstract][Full Text] [Related]
31. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
[TBL] [Abstract][Full Text] [Related]
32. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
33. Reduction of in vitro invasion and in vivo cartilage degradation in a SCID mouse model by loss of function of the fibrinolytic system of rheumatoid arthritis synovial fibroblasts.
Serratì S; Margheri F; Chillà A; Neumann E; Müller-Ladner U; Benucci M; Fibbi G; Del Rosso M
Arthritis Rheum; 2011 Sep; 63(9):2584-94. PubMed ID: 21547898
[TBL] [Abstract][Full Text] [Related]
34. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Ito Y; Takeda T; Kobayashi T; Wakasugi E; Tamaki Y; Umeshita K; Monden T; Shimano T; Monden M
Anticancer Res; 1996; 16(1):81-9. PubMed ID: 8615674
[TBL] [Abstract][Full Text] [Related]
36. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.
Su SC; Lin CW; Yang WE; Fan WL; Yang SF
Expert Opin Ther Targets; 2016; 20(5):551-66. PubMed ID: 26667094
[TBL] [Abstract][Full Text] [Related]
37. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Ahmed N; Riley C; Oliva K; Rice G; Quinn M
Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
[TBL] [Abstract][Full Text] [Related]
38. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
[TBL] [Abstract][Full Text] [Related]
39. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
40. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
